Testing a new antibiotic for resistant Klebsiella infections
Part of Infections clinical trials.
This trial tests a new antibiotic combination (ceftazidime-avibactam) for people with difficult-to-treat Klebsiella pneumoniae infections that are resistant to carbapenem antibiotics due to a specific enzyme. It may help if you have a skin, chest, surgical wound, or urinary tract infection from this resistant bacteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an infection (like a skin, chest, surgical wound, or urinary tract infection) caused by the bacteria Klebsiella pneumoniae.
- The infection is resistant to carbapenem antibiotics, a powerful group of last-resort antibiotics.
- The resistance is specifically due to the bacteria making an enzyme called carbapenemase.
- You do not have infections caused by other types of bacteria, or a Klebsiella infection that is resistant for a different reason.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well the antibiotic cefiderocol works against a type of Klebsiella bacteria that is hard to treat and more likely to cause severe infections. It may help find better treatments for patients with these infections.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
This study tests an antibiotic called ceftazidime-avibactam for people with serious infections like bloodstream infections or pneumonia that started in the hospital or from a breathing machine. It aims to start treatment quickly after identifying the bacteria.
This study tests a precise dosing approach for the antibiotic ceftazidime-avibactam to treat serious infections in ICU patients. It aims to help people with hard-to-treat bacteria that are resistant to many other antibiotics.
This trial tests a new antibiotic combination, cefepime/enmetazobactam, against standard therapy for people with complicated urinary tract infections that have spread to the bloodstream. It aims to see if the new drug works better and is safe.
Hear when a new ISOLATION OF KLEB. by Culture on macConkey Agar trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.